Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Postmenopausal women, Stage III or axillary node positive

• Currently disease free of breast cancer and other invasive malignancies at the time of registration

• No concurrent use of bisphosphonates

Exclusion Criteria:

• Metastatic disease